High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting

AIDS Research and Therapy

Volumn 9, Issue , 2012, Pages

  Puthanakit, Thanyawee ^a,b   Jourdain, Gonzague ^c   Suntarattiwong, Piyarat ^d   Chokephaibulkit, Kulkanya ^e   Siangphoe, Umaporn ^a   Suwanlerk, Tulathip ^a   Prasitsuebsai, Wasana ^a,e   Sirisanthana, Virat ^c   Kosalaraksa, Pope ^f   Petdachai, Witaya ^g   Hansudewechakul, Rawiwan ^h   Waranawat, Naris ^d   Ananworanich, Jintanat ^a,b,i   Bunupuradah, T ^j   Phasomsap, C ^j   Kaew on, P ^j   Kanjanavanit, S ^c   Hinjiranandana, T ^k   Layangool, P ^l   Kamonpakorn, N ^m   Buranabanjasatean, S ⁿ   Ngampiyaskul, C ^o   Chotpitayasunondh, T ^d   Chanpradub, S ^d   Leawsrisuk, P ^d   Chearskul, S ^p   Vanprapar, N ^p   Phongsamart, W ^p   Lapphra, K ^p   Chearskul, P ^p   Wittawatmongkol, O ^p   Prasitsuebsai, W ^p   Intalapaporn, K ^p   Kongstan, N ^p   Pannin, N ^p   Maleesatharn, A ^p   Khumcha, B ^p   Aurpibul, L ^c   Wongnum, N ^c   Nadsasarn, R ^c   Lumbiganon, P ^q   Tharnprisan, P ^q   Udompanich, T ^q   Yentang, M ^g   Khonponoi, A ^h   Maneerat, N ^h   Denjunta, S ^h   WatanapornS , ^h   Yodsuwan, C ^h   Srisuk, W ^h   Somsri, S ^h   Surapanichadul, K ^h   more..

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f KHON KAEN UNIVERSITY   (Thailand)

^g Petchburi Hospital   (Thailand)

^h Chiang Rai Regional Hospital   (Thailand)

ⁱ Chiang Rai Regional Hospital ^*  (Thailand)

^j THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^k NAKORNPING HOSPITAL   (Thailand)

^l BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

^m Somdej Prapinklao Hospital   (Thailand)

ⁿ Mae Chan Hospital   (Thailand)

^o Prapokklao Provincial Hospital   (Thailand)

^p MAHIDOL UNIVERSITY   (Thailand)

^q KHON KAEN UNIVERSITY   (Thailand)

more..

Author keywords

Drug resistance; Pediatric HIV; Protease inhibitors; Resource limited settings; Second line antiretroviral therapy

Indexed keywords

CD4 ANTIBODY; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ARTICLE; BLURRED VISION; CHILD; CLINICAL DECISION MAKING; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

EID: 84862259247     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-9-20     Document Type: Article

References (28)

1. Ciaranello AL, Chang Y, Margulis AV, Bernstein A, Bassett IV, Losina E, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis 2009 Dec 15, 49(12):1915-27.
2. Kariminia A, Chokephaibulkit K, Pang J, Lumbiganon P, Hansudewechakul R, Amin J, et al. Cohort profile: the TREAT Asia pediatric HIV observational database. Int J Epidemiol 2011 Feb, 40(1):15-24.
3. Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005 Jul 1, 41(1):100-7.
4. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. Journal of acquired immune deficiency syndromes 2007, 46(2):187-93. 10.1097/QAI.0b013e31814278c0, 17693883.
5. Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007 Nov, 120(5):e1134-40.
6. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J 2008, 27(11):993-8. 10.1097/INF.0b013e31817acf7b, 18818556.
7. Prasitsuebsai W, Bowen AC, Pang J, Hesp C, Kariminia A, Sohn AH. Pediatric HIV clinical care resources and management practices in Asia: a regional survey of the TREAT Asia pediatric network. AIDS Patient Care STDS 2010, 24(2):127-31. 10.1089/apc.2009.0224, 2835391, 20059355.
8. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection Available at: ≤http://www.pentatrials.org/guide09.pdf≥ (Accessed: July 31, 2009), PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.
9. Working Group on Antiretroviral Therapy and Medical Managment of HIV-infected children Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, February 23, 2009 2009, US Department of Health and Human Services: Access, http://AIDSinfo.nih.gov/, Working Group on Antiretroviral Therapy and Medical Managment of HIV-infected children.
10. Resino S, Bellon JM, Ramos JT, Navarro ML, Martin-Fontelos P, Cabrero E, et al. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004, 23(10):923-30. 10.1097/01.inf.0000142170.52155.7f, 15602192.
11. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007 Feb 1, 44(3):447-52.
12. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2009, 28(9):826-30. 10.1097/INF.0b013e3181a458f9, 19654564.
13. Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, et al. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV medicine 2010, 11(9):565-72. 10.1111/j.1468-1293.2010.00828.x, 20345882.
14. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, et al. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther 2009, 14(2):241-8.
15. Thai Ministry of Public Health Thai National guideline for managment of HIV-infected children and adults 2004, ISBN 974-297-2982, Thai Ministry of Public Health.
16. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS (London, England) 2003, 17(13):1889-96.
17. World Health Organization Antiretroviral therapy for HIV infection in infants and children: towards universal access 2010, Recommendations for a public health approach, World Health Organization.
18. Kline MW, Rugina S, Ilie M, Matusa RF, Schweitzer AM, Calles NR, et al. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy. Pediatrics 2007 May, 119(5):e1116-20.
19. De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. Int J Immunopathol Pharmacol 2005, 18(4):729-35.
20. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV medicine 2010, 11(8):510-8.
21. Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008, 27(7):623-8. 10.1097/INF.0b013e31816b4539, 18520443.
22. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, et al. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV medicine 2007, 8(8):529-35. 10.1111/j.1468-1293.2007.00506.x, 17944686.
23. Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens: the HIV STAR study. Antivir Ther 2012, Jul 2 [Epub ahead of print].
24. Manosuthi W, Kiertiburanakul S, Amornnimit W, Prasithsirikul W, Thongyen S, Nilkamhang S, et al. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. AIDS Res Ther 2009, 6:30. 10.1186/1742-6405-6-30, 2805683, 20030841.
25. Perez-Valero I, Arribas JR. Protease inhibitor monotherapy. Curr Opin Infect Dis 24(1):7-11.
26. Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One 2011, 6(7):e22003. 10.1371/journal.pone.0022003, 3139616, 21811554.
27. Antiretroviral therapy for HIV infection in infants and children towards universal access Recommendation for public health approach: 2010 revision Available at: ≤http://www.who.int/hiv/topics/paediatric/en/index.html≥ (Access September 2, 2010).
28. Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011, (4):273-83.